Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services ...

In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe’s assets for $256 million, including its personal genome service, research services, biobank, and ...

In response to questions about the lawsuit, Regeneron, which is based in Tarrytown in New York's lower Hudson Valley, noted in a statement that the 23andMe bankruptcy auction has been reopened and ...

23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.

23andMe filed for for Chapter 11 bankruptcy protection in March. Last month, Regeneron announced that it would purchase most of 23andMe's assets for $256 million, but it was outbid.

Regeneron Pharmaceuticals (REGN) exits buyout race for 23andMe as Anne Wojcicki's TTAM Research offers a superior $305M bid. Read more here.